Hypothesis

Senescent cells actively restrict proliferation of neighboring stem and progenitor cells by consuming glutamine and using it to acetylate ARID‑containing lysine demethylases (KDMs). This epigenetic shift biases the senescence‑associated secretory phenotype (SASP) toward TGF‑β‑ and PDGF‑AA‑rich factors that enforce a microenvironmental block on mTORC1 signaling in adjacent cells. When senescent cells are cleared, the glutamine sink disappears, extracellular glutamine rises, ARID‑KDM acetylation in surviving cells shifts, and the SASP skews toward pro‑inflammatory IL‑6/IL‑8 ligands, lifting the proliferative restraint and potentially unleashing tumorigenesis in damaged tissue.

Mechanistic Rationale

Recent work shows senescent fibroblasts are heterogeneous, with subpopulations secreting either reparative (PDGF‑AA, TGF‑β) or inflammatory (IL‑6, IL‑8) factors depending on metabolic and epigenetic states【4】【5】. Glutamine fuels the acetylation of ARID domains on KDM enzymes, altering histone demethylase activity and transcriptional programs【8】. Senescent cells upregulate glutaminase (GLS) and glutamine transporters (SLC1A5), creating a local glutamine‑depleted niche that limits mTORC1 activity in neighboring cells, thereby suppressing cell‑cycle progression. The resulting SASP, enriched in TGF‑β and PDGF‑AA, reinforces this block through SMAD‑dependent transcription of cyclin‑dependent kinase inhibitors (p21, p16).

When senescent cells are removed with senolytics (e.g., D+Q, fisetin)【2】, glutamine rebounds, leading to hyper‑acetylation of ARID‑KDMs in remaining stromal and epithelial cells. This drives a SASP switch toward NF‑κB‑dependent cytokines (IL‑6, IL‑8) that activate STAT3 and mTORC1, promoting proliferation. In contexts where DNA damage or oncogenic stress persists, this proliferative surge can initiate or accelerate tumorigenesis—a scenario supported by observations that chronic senescence accumulation correlates with both tissue repair failure and cancer promotion【2】【3】.

Testable Predictions

1. Metabolic: Senescent cells will show higher GLS activity and SLC1A5 expression than non‑senescent counterparts; inhibiting GLS will recapitulate the SASP shift seen after senolytic clearance.
2. Epigenetic: ARID‑KDM acetylation levels will be elevated in senescent cells and drop upon glutamine depletion; rescuing acetylation with glutamine supplementation will restore the TGF‑β/PDGF‑AA‑rich SASP.
3. Functional: Conditioned medium from glutamine‑deprived senescent cells will suppress mTORC1 signaling (reduced p‑S6K) in co‑cultured stem cells, whereas medium from senolytic‑cleared cultures will increase p‑S6K and proliferation.
4. In vivo: In aged mice with inducible p16‑positive senescence and oncogenic KRAS activation, senolytic treatment will increase interstitial glutamine (measured by microdialysis), elevate ARID‑KDM acetylation in keratinocytes, and raise squamous cell carcinoma incidence compared with controls receiving a GLS inhibitor alongside the senolytic.

Experimental Approach

• Isolate primary human fibroblasts, induce senescence via irradiation, and quantify GLS, SLC1A5, and ARID‑KDM acetylation by western blot and targeted proteomics【7】.
• Perform glutamine flux assays using ^13C‑glutamine tracing to measure intracellular vs. extracellular pools.
• Collect conditioned media under normal, GLS‑inhibited (CB-839), and glutamine‑repleted conditions; run multiplex cytokine arrays to map SASP composition.
• Treat murine skin organoids with these media and assess p‑S6K, EdU incorporation, and apoptosis.
• Conduct longitudinal studies in p16‑3MR mice bearing a KRAS^G12D allele, administering D+Q ± CB-839, tracking glutamine levels via PET imaging, SASP shifts via spatial transcriptomics【5】, and tumor onset.

If these predictions hold, the data will reframe senolytics not merely as clearance agents but as modulators of a glutamine‑dependent epigenetic checkpoint, guiding combination therapies that preserve beneficial SASP while mitigating post‑clearance proliferative risks.